stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Gross margin
Zai Lab Limited Unsponsored ADR's gross margin over the twelve months to 30 September 2026 was 0.00%, down 58.5 percentage points from fiscal 2025 (58.5%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 71.1% (fiscal 2019); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 58.5% | (4.47) |
| FY2024 | 62.9% | (1.14) |
| FY2023 | 64.1% | (1.50) |
| FY2022 | 65.6% | 1.78 |
| FY2021 | 63.8% | (2.02) |
| FY2020 | 65.8% | (5.31) |
| FY2019 | 71.1% | 4.46 |
| FY2018 | 66.7% | 66.67 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (54.70) |
| Jun 2026 | 54.7% | (6.82) |
| Mar 2026 | 61.5% | 10.37 |
| Dec 2025 | 51.2% | (8.47) |
| 28 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| XNCR Xencor, Inc. compare | 100.0% |
| RCUS Arcus Biosciences, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | 100.0% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 29.2% |
| ZLAB Zai Lab Limited Unsponsored ADR | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement